PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10421620-7	1999	The enzyme activity was significantly (p <.01) and stereoselectively inhibited by CYP2D1 inhibitors quinine and quinidine (not by CYP2C or CYP3A inhibitors), and by anti-CYP2D6 peptide antiserum (not by anti-CYP2C, -CYP2B, or -CYP3A antibodies).	Quinine	103-110	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	85-91	
9721180-9	1998	The human CYP2D6-specific inhibitor quinidine and the rat CYP2D1-specific inhibitor quinine were both shown to be inhibitors of bufuralol 1"-hydroxylase activity for dog liver microsomes, CYP2D15 WT2, and the CYP2D15 V1 variant with nearly equal potency.	Quinine	84-91	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	58-64	
9067326-4	1997	In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) produced a marked suppression in brain and plasma hydromorphone levels detected after the peripheral administration of hydrocodone, thus confirming that the doses used suppressed CYP2D1 activity.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	231-237	
7835220-7	1994	The main enzyme concerned in the 1- and 8-hydroxylation of both enantiomers is considered to be CYP2D1 from the following observation: the marked strain differences between Sprague-Dawley and Dark Agouti rats and competitive inhibition by quinine.	Quinine	239-246	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	96-102	
9413916-8	1997	Quinine (Ki = 0.06 microM) and quinidine (Ki = 2.0 microM), selective inhibitors of CYP2D1, competitively inhibited 8-hydroxycarteolol formation.	Quinine	0-7	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	84-90	
9833017-2	1997	To determine the impact of impaired AMP metabolism on its behavioural effects, AMP-induced hyperactivity, AMP discrimination and AMP self-administration were examined in male Wistar rats with or without pretreatment with the CYP2D1 inhibitors quinine and budipine.	Quinine	243-250	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	225-231	
9833017-3	1997	In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) increased the plasma area under the curve of AMP 4-fold and 3.6-fold respectively, and decreased the plasma levels of 4-OH-AMP, 3-fold and 8.6-fold, confirming that the doses used suppressed CYP2D1 activity.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	243-249	
9105413-7	1997	The contribution of CYP2D1 to the O-dealkylation of EM/NEM and CD/NCD was further confirmed by use of the specific CYP2D1 inhibitors quinine and propafenone.	Quinine	133-140	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	20-26	
9105413-7	1997	The contribution of CYP2D1 to the O-dealkylation of EM/NEM and CD/NCD was further confirmed by use of the specific CYP2D1 inhibitors quinine and propafenone.	Quinine	133-140	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	115-121	
8586645-6	1995	Quinine and quinidine showed 400 and 80 times, respectively, higher affinity for MBP than for debrisoquine 4-hydroxylase.	Quinine	0-7	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	94-120	
8185638-7	1994	By using quinine as a specific inhibitor of the enzyme, CYP2D1 was identified as an intermediate affinity site in the Wistar strain and was shown to have impaired activity in the DA strain.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	56-62